BioSpace News Archive

Deals

CG Oncology’s Upsized $380M IPO is First Biotech to Go Public in 2024

The bladder cancer-focused company’s larger-than-expected Nasdaq debut on Thursday opens this year’s batch of planned initial public offerings, which include at least half a dozen biotechs.

January 25, 2024
·
2 min read
·
Tristan Manalac
Employer Resources

What can biopharma expect from the job market?

BioSpace’s Lori Ellis and Chantal Dresner discuss anticipated job market trends for 2024 including unemployment, anticipated job search activity and hiring trends.

January 25, 2024
·
1 min read
·
BioSpace Insights
Policy

FDA Reveals More Details on 22 CAR-T Secondary Cancer Cases

The FDA’s Peter Marks and Nicole Verdun in the NEJM Wednesday disclosed that more than 27,000 CAR-T doses have been administered in the U.S. as of the end of 2023, of which there are 22 cases of T-cell cancers.

January 25, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Experts Take a ‘Wait and See’ Approach as BTK Inhibitors Stumble in MS

Despite myriad stumbling blocks over the past two years, experts still see the potential of Bruton’s tyrosine kinase inhibitors to quiet progressive multiple sclerosis.

January 25, 2024
·
6 min read
·
Jill Neimark
Drug Development

Chinese Gene Therapy Restores Hearing in Five of Six Treated Children

After 26 weeks of follow-up, five of six children treated with an experimental gene therapy developed in China showed strong improvements in speech perception and could hold normal conversations.

January 25, 2024
·
2 min read
·
Tristan Manalac
Policy

Suspected Fake Ozempic Tied to Three Severe U.S. Cases of Hypoglycemia: Reuters

More than 3,000 people in the U.S. suffered from side effects of Ozempic in 2023, according to exclusive reporting on Wednesday from Reuters citing data from America’s Poison Centers.

January 25, 2024
·
2 min read
·
Tristan Manalac
Policy

FDA Misses PDUFA Date for Liquidia’s NDA for Inhaled Blood Pressure Drug

After missing its Jan. 24 PDUFA date, the regulator has extended its review period but has not issued a new decision timeframe or requested additional data, Liquidia announced Thursday.

January 25, 2024
·
1 min read
·
Kate Goodwin
Drug Development

Roche, Exelixis Score Phase III Prostate Cancer Win for Cabometyx-Tecentriq Combo

In the CONTACT-02 pivotal trial, the combination of Exelixis’ Cabometyx and Roche’s Tecentriq reduced the risk of disease progression or death by 35% in patients with metastatic castration-resistant prostate cancer.

January 25, 2024
·
3 min read
·
Tyler Patchen
BD Helps Advance Health Equity for Women in Kenya through Critical Cancer Screening

BD announced a collaboration with the Kenyan Government through the National Cancer Institute-Kenya to advance access to critical cancer diagnostics for women in Kenya.

January 25, 2024
·
5 min read
BioCapital

LUNGevity Issues RFA Focused on Immunotherapy Resistance in Lung Cancer

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is pleased to issue an RFA (Request for Application) for the Brown/LUNGevity Award to Understand Mechanisms of Resistance to Immunotherapy.

January 25, 2024
·
3 min read